CY1115446T1 - Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης - Google Patents

Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης

Info

Publication number
CY1115446T1
CY1115446T1 CY20141100523T CY141100523T CY1115446T1 CY 1115446 T1 CY1115446 T1 CY 1115446T1 CY 20141100523 T CY20141100523 T CY 20141100523T CY 141100523 T CY141100523 T CY 141100523T CY 1115446 T1 CY1115446 T1 CY 1115446T1
Authority
CY
Cyprus
Prior art keywords
treatment
allogenic cells
operative infection
allogeneic cells
cells
Prior art date
Application number
CY20141100523T
Other languages
English (en)
Inventor
Michael Har-Noy
Original Assignee
Immunovative Therapies, Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunovative Therapies, Ltd. filed Critical Immunovative Therapies, Ltd.
Publication of CY1115446T1 publication Critical patent/CY1115446T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/461—Cellular immunotherapy characterised by the cell type used
    • A61K39/4611—T-cells, e.g. tumor infiltrating lymphocytes [TIL], lymphokine-activated killer cells [LAK] or regulatory T cells [Treg]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/46—Cellular immunotherapy
    • A61K39/464—Cellular immunotherapy characterised by the antigen targeted or presented
    • A61K39/4641—Fungal antigens, e.g. Trichophyton, Aspergillus or Candida
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/122—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells for inducing tolerance or supression of immune responses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/26—Universal/off- the- shelf cellular immunotherapy; Allogenic cells or means to avoid rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K39/46
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K39/46 characterised by the dose, timing or administration schedule

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Zoology (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Μια μέθοδος για την διέγερση του ανοσιακού συστήματος σε ανοσοκατασταλμένους ασθενείς προκειμένου να υποβληθεί σε αγωγή η ευκαιριακή λοίμωξη. Η μέθοδος ενέχει την έγχυση εκ προθέσεως αναντίστοιχων αλλογενών κυττάρων. Προκειμένου να αποτραπούν οι επιπλοκές της πάθησης μοσχεύματος-έναντι-ξενιστή, τα αλλογενή κύτταρα μπορούν να ακτινοβοληθούν προ της έγχυσης.
CY20141100523T 2006-04-13 2014-07-11 Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης CY1115446T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06750196.5A EP2003978B1 (en) 2006-04-13 2006-04-13 Allogeneic cell therapy for treatment of opportunistic infection
PCT/US2006/014088 WO2007120128A1 (en) 2006-04-13 2006-04-13 Allogeneic cell therapy for treatment of opportunistic infection

Publications (1)

Publication Number Publication Date
CY1115446T1 true CY1115446T1 (el) 2017-01-04

Family

ID=38609793

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20141100523T CY1115446T1 (el) 2006-04-13 2014-07-11 Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης

Country Status (11)

Country Link
EP (1) EP2003978B1 (el)
JP (1) JP5254952B2 (el)
CA (1) CA2649290C (el)
CY (1) CY1115446T1 (el)
DK (1) DK2003978T3 (el)
ES (1) ES2482141T3 (el)
IL (1) IL194667A (el)
PL (1) PL2003978T3 (el)
PT (1) PT2003978E (el)
SI (1) SI2003978T1 (el)
WO (1) WO2007120128A1 (el)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7435592B2 (en) 2003-05-13 2008-10-14 Immunovative Therapies, Ltd. Compositions for allogeneic cell therapy
US20120128656A1 (en) 2008-05-02 2012-05-24 Immunovative Therapies, Ltd. Vaccine compositions and methods
WO2011130249A2 (en) * 2010-04-13 2011-10-20 Immunovative Therapies, Ltd. Methods and compositions for inhibition of treg cells
CA2799516C (en) * 2010-08-06 2016-01-05 Canine-Lab.Inc. Immunological function enhancing agent
EP2704732B1 (en) 2011-05-03 2020-03-04 Immunovative Therapies, Ltd. Induction of il-12 using immunotherapy
TWI676481B (zh) * 2012-05-02 2019-11-11 以色列商梵提夫免疫療法公司 使用免疫療法誘導ｉｌ－１２
CA2782942C (en) 2012-07-12 2019-08-27 Canadian Blood Services Method for inducing immune tolerance using polymer-modified antigenic leukocytes
DK3019176T3 (da) 2013-07-12 2020-06-22 Canadian Blood Services Anvendelse af acellulære pro-inflammatoriske sammensætninger og fremgangsmåde til fremstilling heraf
EP3166618B1 (en) 2014-07-10 2021-01-13 Canadian Blood Services Combination therapy of a cellular pro-tolerogenic and pro-inflammatory preparations for modulating the immune system

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6156312A (en) * 1993-06-23 2000-12-05 Leskovar; Peter Agents, affecting the hyperactivated immunological effector cells

Also Published As

Publication number Publication date
DK2003978T3 (da) 2014-07-07
EP2003978A1 (en) 2008-12-24
EP2003978A4 (en) 2009-07-22
PL2003978T3 (pl) 2014-12-31
CA2649290A1 (en) 2007-10-25
JP5254952B2 (ja) 2013-08-07
SI2003978T1 (sl) 2014-11-28
EP2003978B1 (en) 2014-06-11
IL194667A (en) 2015-06-30
WO2007120128A1 (en) 2007-10-25
PT2003978E (pt) 2014-07-25
ES2482141T3 (es) 2014-08-01
JP2009533430A (ja) 2009-09-17
CA2649290C (en) 2017-04-04

Similar Documents

Publication Publication Date Title
CY1115446T1 (el) Θεραπεια αλλογενων κυτταρων για την αγωγη ευκαιριακης λοιμωξης
WO2011056688A3 (en) Molecular profiling for personalized medicine
CY1120360T1 (el) Μεθοδος για την προωθηση της αγγειογενεσης, της αγγειωσης ή της αποκαταστασης των αγγειων, ή για την αναστολη της αγγειογενεσης ογκων
CY1116090T1 (el) Μεθοδος για σχηματισμο γελης φιμπροϊνης μεταξης χρησιμοποιωντας κατεργασια υπερηχων
MX2011013452A (es) Tratamiento de cancer basado en exosomas.
AR055038A1 (es) Metodo y compuesto para tratar enfermedades vasculares perifericas
BRPI0606108A2 (pt) processo de tratamento
CY1125948T1 (el) Σχημα αγωγης που χρησιμοποιει νερατινιμπη για τον καρκινο του μαστου
DK2023918T3 (da) Cyclosporiner til behandlingen og forebyggelse af okulære lidelser
EA201001695A1 (ru) Применение эпотилона d для лечения заболеваний, связанных с тау-белком
ATE520007T1 (de) Bildgebungsgeometrie
EA201001691A1 (ru) Антитела к гранулоцитарно-макрофагальному колониестимулирующему фактору
CY1121973T1 (el) Θεραπεια φαρμακευτικα ανθεκτικου καρκινου η οποια στοχευει καρκινικα βλαστοκυτταρα
MX2011008994A (es) Metodos de usar sns - 595 para el tratamiento de sujetos con cancer con actividad reducida de brca2.
EA201390417A1 (ru) Антидиабетические твердые фармацевтические композиции
UA110325C2 (en) Medicinal carbohydrates for treating respiratory conditions
EP2579863A4 (en) COMPOUNDS FOR THE TREATMENT OF BOVINE MASTITIS
MX2011012538A (es) Terapia de combinacion para el tratamiento del mieloma multiple.
AR060897A1 (es) Metodo de vacunacion de sujetos que reciben terapia de inmunomodulacion
RU2008129232A (ru) Способ лечения туберкулеза легких у больных вич-инфекцией
RU2011108787A (ru) Способ лечения больных красным плоским лишаем слизистой полости рта
UA35013U (ru) Способ лечения больных брюшным тифом с наличием вторичного иммунодефицита
RU2009142007A (ru) Способ лечения вазомоторного ринита
MX2011005054A (es) Uso combinado de bendamustina, doxorubicina y bortezomib para el tratamiento del mieloma multiple.
RU2008130241A (ru) Способ и средство для реабилитации детей с хроническими риносинуситами